MCDA Hemlibra® in haemophilia A with inhibitors

//MCDA Hemlibra® in haemophilia A with inhibitors

MCDA Hemlibra® in haemophilia A with inhibitors

Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Avaliable at: https://journals.sagepub.com/doi/full/10.1177/2284240319880534

2020-09-23T17:55:44+00:00October 8th, 2019|Articles|

Leave A Comment

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our cookies policy, Click on the link for more information. ACEPTAR

Aviso de cookies